financetom
Business
financetom
/
Business
/
Mastek buys US-based BizAnalytica in boost for generative AI, global cloud capabilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mastek buys US-based BizAnalytica in boost for generative AI, global cloud capabilities
Jul 19, 2023 9:17 AM

IT company Mastek Ltd on Wednesday (July 19) said it has acquired BizAnalytica, a premier data cloud and modernisation solutions provider headquartered in Boston, USA.

Share Market Live

NSE

The strategic acquisition will bolster Mastek's global data cloud services and generative AI capabilities and grant access to a talented pool of qualified data architects and scientists, according to a stock exchange filing.

Established in 2017, BizAnalytica offers end-to-end data cloud and modernisation solutions, including architectural design, system integration, data migration, automation, management, warehousing, and analytics. The company's expertise empowers enterprises to make intelligent, data-driven decisions that drive revenue growth.

A notable aspect of BizAnalytica's portfolio is its strategic partnerships with leading cloud platforms, such as Snowflake, Databricks, and AWS, further solidifying its position in the market, it said.

Hiral Chandrana, CEO of Mastek Group, said this acquisition marks a pivotal milestone in accelerating the company’s presence in data engineering, cloud services, and the rapidly-evolving generative AI domain.

BizAnalytica's strong data cloud and modernisation capabilities, along with its valuable partnerships with industry-leading cloud platforms, will enable us to decomplex the cloud transformation journey for our clients, delivering trust, value, and velocity, he said.

Lokesh Khosla, CTO and Co-Founder of BizAnalytica, said, "We firmly believe that Mastek is the ideal partner to reinforce our market-specific capabilities in data cloud and generative AI. This transition marks a turning point for BizAnalytica, and we eagerly anticipate collaborating with our joint customers in their transformation journey."

Shares of Mastek Ltd ended at Rs 2,177.00, up by Rs 24.15, or 1.12 percent on the BSE.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint
Apr 8, 2024
06:10 AM EDT, 04/08/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday that a phase 2 study evaluating the investigational drug zilebesiran in treating hypertension has met its primary endpoint. Zilebesiran reached the study's primary endpoint after demonstrating statistically significant reductions in systolic blood pressure in three months, the company said. Most laboratory abnormalities of interest were mild,...
Guyana gas-to-power project to shave weeks off oil output, hit revenue
Guyana gas-to-power project to shave weeks off oil output, hit revenue
Apr 8, 2024
GEORGETOWN (Reuters) - Guyana's efforts to use its natural gas resources to fuel a power plant that would slash the South American nation's energy costs have snagged on construction delays and threaten to curtail the rising oil hotspot's revenue this year by about $1 billion. The $1.9 billion gas-to-power project, Guyana's biggest effort to capitalize on its energy bounty, is...
Major food companies offering deals, new sizes as low-income Americans spend less
Major food companies offering deals, new sizes as low-income Americans spend less
Apr 8, 2024
NEW YORK (Reuters) - Americans relying on government benefits to buy food and other essentials are slashing spending, prompting food makers like Kraft-Heinz ( KHC ) and Conagra Brands ( CAG ) to overhaul their products and strategies following years of price hikes. Many of the biggest makers of packaged foods and drinks are seeing their sales volumes fall, due...
Exclusive-Synchron, a rival to Musk's Neuralink, readies large-scale brain implant trial
Exclusive-Synchron, a rival to Musk's Neuralink, readies large-scale brain implant trial
Apr 8, 2024
WASHINGTON (Reuters) - Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters. Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved